Glycated Proteins in Elderly Type II Diabetic Patients: Role of Age and Serum Protein Concentration

Carroccio, Antonio; Montalto, Giuseppe; Soresi, Maurizio; Lupo, Roberto; Martino, Daniela Di; Notarbartoló, A

doi:10.1093/ageing/20.5.349

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fructosamine has also been found to be unreliable in certain circumstances, because results can be influenced by a range of chronic conditions rather than by metabolic control. 163 Whereas the HbA 1c concentration depends largely on the ambient glucose concentration and haemoglobin levels of patients, the concentration of fructosamine depends mainly on the concentration of glucose and albumin. Evidence from in vitro studies suggests that the amount of fructosamine formed is more closely related to albumin concentration than to glucose concentration.…”

Section: Standardisation Of Fructosamine Testingmentioning

confidence: 99%

Monitoring blood glucose control in diabetes mellitus: a systematic review.

Coster¹,

Gulliford

Seed

et al. 2000

Health Technology Assessment

205

View full text Add to dashboard Cite

Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see overleaf). NHS R&D HTA ProgrammeT he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources.The Standing Group on Health Technology advises on national priorities for health technology assessment. Six advisory panels assist the Standing Group in identifying and prioritising projects. These priorities are then considered by the HTA Commissioning Board supported by the National Coordinating Centre for HTA (NCCHTA).This report is one of a series covering acute care, diagnostics and imaging, methodology, pharmaceuticals, population screening, and primary and community care. It was identified as a priority by the Diagnostics and Imaging Panel and funded as project number 96/10/03.The views expressed in this publication are those of the authors and not necessarily those of the Standing Group, the Commissioning Board, the Panel members or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for the recommendations for policy contained herein. In particular, policy options in the area of screening will be considered by the National Screening Committee. This Committee, chaired by the Chief Medical Officer, will take into account the views expressed here, further available evidence and other relevant considerations.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work either prioritised by the Standing Group on Health Technology, or otherwise commissioned for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

Section: Standardisation Of Fructosamine Testingmentioning

confidence: 99%